The CEO submitted claims with codes for services that were never performed and received payments from more than one source for the same test.

The partners intend to develop a point-of-care testing instrument that can be used to aid the diagnosis of cancers and other diseases.

Last week, readers were most interested in a story about Waters acquiring BD's biosciences and diagnostics solutions business.

Premier Medical owner and CEO Kevin Murdock paid kickbacks for cancer genetic testing referrals, defrauding Georgia, Colorado, and South Carolina Medicaid, DOJ said.

The company also offers platform-agnostic next-generation sequencing tests and a suite of sample prep and thermal cycling instruments.

The Boston-based digital pathology firm's updated US Food and Drug Administration clearance will help it to quickly validate its software with new hardware combinations.

FulgentExome, which covers more than 4,600 genes validated for diagnostic use, is now authorized under Europe's In Vitro Diagnostic Regulation.

The firm saw growth in its core laboratory segment but declines in molecular, point of care, and rapid diagnostics.

The US Food and Drug Administration granted clearances for infectious disease tests, digital pathology software, and hematology analyzers, among other in vitro diagnostic technologies.

The agency said that the test is unnecessary for the screening of whole blood and blood components that are screened with nucleic acid tests and core antigen tests.

NEW YORK – Phase Scientific said Wednesday that has signed an exclusive US distribution agreement with Lumos Diagnostics for a 10-minute point-of-care blood test to distinguish bacterial and ...